Evaluation of distal symmetric polyneuropathy

The role of autonomic testing, nerve biopsy, and skin biopsy (an evidence-based review)

J. D. England, G. S. Gronseth, G. Franklin, G. T. Carter, L. J. Kinsella, J. A. Cohen, A. K. Asbury, K. Szigeti, J. R. Lupski, N. Latov, R. A. Lewis, P. A. Low, M. A. Fisher, D. Herrmann, J. F. Howard, G. Lauria, R. G. Miller, M. Polydefkis, A. J. Sumner

Research output: Contribution to journalArticle

53 Citations (Scopus)

Abstract

Distal symmetric polyneuropathy (DSP) is the most common variety of neuropathy. Since the evaluation of this disorder is not standardized, the available literature was reviewed to provide evidence-based guidelines regarding the role of autonomic testing, nerve biopsy, and skin biopsy for the assessment of polyneuropathy. A literature review using MEDLINE, EMBASE, Science Citation Index, and Current Contents was performed to identify the best evidence regarding the evaluation of polyneuropathy published between 1980 and March 2007. Articles were classified according to a four-tiered level of evidence scheme and recommendations were based on the level of evidence. (1) Autonomic testing may be considered in the evaluation of patients with polyneuropathy to document autonomic nervous system dysfunction (Level B). Such testing should be considered especially for the evaluation of suspected autonomic neuropathy (Level B) and distal small fiber sensory polyneuropathy (SFSN) (Level C). A battery of validated tests is recommended to achieve the highest diagnostic accuracy (Level B). (2) Nerve biopsy is generally accepted as useful in the evaluation of certain neuropathies as in patients with suspected amyloid neuropathy, mononeuropathy multiplex due to vasculitis, or with atypical forms of chronic inflammatory demyelinating polyneuropathy (CIDP). However, the literature is insufficient to provide a recommendation regarding when a nerve biopsy may be useful in the evaluation of DSP (Level U). (3) Skin biopsy is a validated technique for determining intraepidermal nerve fiber (IENF) density and may be considered for the diagnosis of DSP, particularly SFSN (Level C). There is a need for additional prospective studies to define more exact guidelines for the evaluation of polyneuropathy.

Original languageEnglish
Pages (from-to)106-115
Number of pages10
JournalMuscle and Nerve
Volume39
Issue number1
DOIs
Publication statusPublished - Jan 2009

Fingerprint

Autonomic Pathways
Polyneuropathies
Biopsy
Skin
Amyloid Neuropathies
Guidelines
Chronic Inflammatory Demyelinating Polyradiculoneuropathy
Mononeuropathies
Autonomic Nervous System
Vasculitis
Nerve Fibers
MEDLINE
Prospective Studies

Keywords

  • Distal symmetric polyneuropathy
  • Evaluation
  • Prospective studies

ASJC Scopus subject areas

  • Clinical Neurology
  • Cellular and Molecular Neuroscience
  • Physiology (medical)
  • Physiology

Cite this

England, J. D., Gronseth, G. S., Franklin, G., Carter, G. T., Kinsella, L. J., Cohen, J. A., ... Sumner, A. J. (2009). Evaluation of distal symmetric polyneuropathy: The role of autonomic testing, nerve biopsy, and skin biopsy (an evidence-based review). Muscle and Nerve, 39(1), 106-115. https://doi.org/10.1002/mus.21227

Evaluation of distal symmetric polyneuropathy : The role of autonomic testing, nerve biopsy, and skin biopsy (an evidence-based review). / England, J. D.; Gronseth, G. S.; Franklin, G.; Carter, G. T.; Kinsella, L. J.; Cohen, J. A.; Asbury, A. K.; Szigeti, K.; Lupski, J. R.; Latov, N.; Lewis, R. A.; Low, P. A.; Fisher, M. A.; Herrmann, D.; Howard, J. F.; Lauria, G.; Miller, R. G.; Polydefkis, M.; Sumner, A. J.

In: Muscle and Nerve, Vol. 39, No. 1, 01.2009, p. 106-115.

Research output: Contribution to journalArticle

England, JD, Gronseth, GS, Franklin, G, Carter, GT, Kinsella, LJ, Cohen, JA, Asbury, AK, Szigeti, K, Lupski, JR, Latov, N, Lewis, RA, Low, PA, Fisher, MA, Herrmann, D, Howard, JF, Lauria, G, Miller, RG, Polydefkis, M & Sumner, AJ 2009, 'Evaluation of distal symmetric polyneuropathy: The role of autonomic testing, nerve biopsy, and skin biopsy (an evidence-based review)', Muscle and Nerve, vol. 39, no. 1, pp. 106-115. https://doi.org/10.1002/mus.21227
England, J. D. ; Gronseth, G. S. ; Franklin, G. ; Carter, G. T. ; Kinsella, L. J. ; Cohen, J. A. ; Asbury, A. K. ; Szigeti, K. ; Lupski, J. R. ; Latov, N. ; Lewis, R. A. ; Low, P. A. ; Fisher, M. A. ; Herrmann, D. ; Howard, J. F. ; Lauria, G. ; Miller, R. G. ; Polydefkis, M. ; Sumner, A. J. / Evaluation of distal symmetric polyneuropathy : The role of autonomic testing, nerve biopsy, and skin biopsy (an evidence-based review). In: Muscle and Nerve. 2009 ; Vol. 39, No. 1. pp. 106-115.
@article{5849d8ecdeb14304ade81c17dbb5d72e,
title = "Evaluation of distal symmetric polyneuropathy: The role of autonomic testing, nerve biopsy, and skin biopsy (an evidence-based review)",
abstract = "Distal symmetric polyneuropathy (DSP) is the most common variety of neuropathy. Since the evaluation of this disorder is not standardized, the available literature was reviewed to provide evidence-based guidelines regarding the role of autonomic testing, nerve biopsy, and skin biopsy for the assessment of polyneuropathy. A literature review using MEDLINE, EMBASE, Science Citation Index, and Current Contents was performed to identify the best evidence regarding the evaluation of polyneuropathy published between 1980 and March 2007. Articles were classified according to a four-tiered level of evidence scheme and recommendations were based on the level of evidence. (1) Autonomic testing may be considered in the evaluation of patients with polyneuropathy to document autonomic nervous system dysfunction (Level B). Such testing should be considered especially for the evaluation of suspected autonomic neuropathy (Level B) and distal small fiber sensory polyneuropathy (SFSN) (Level C). A battery of validated tests is recommended to achieve the highest diagnostic accuracy (Level B). (2) Nerve biopsy is generally accepted as useful in the evaluation of certain neuropathies as in patients with suspected amyloid neuropathy, mononeuropathy multiplex due to vasculitis, or with atypical forms of chronic inflammatory demyelinating polyneuropathy (CIDP). However, the literature is insufficient to provide a recommendation regarding when a nerve biopsy may be useful in the evaluation of DSP (Level U). (3) Skin biopsy is a validated technique for determining intraepidermal nerve fiber (IENF) density and may be considered for the diagnosis of DSP, particularly SFSN (Level C). There is a need for additional prospective studies to define more exact guidelines for the evaluation of polyneuropathy.",
keywords = "Distal symmetric polyneuropathy, Evaluation, Prospective studies",
author = "England, {J. D.} and Gronseth, {G. S.} and G. Franklin and Carter, {G. T.} and Kinsella, {L. J.} and Cohen, {J. A.} and Asbury, {A. K.} and K. Szigeti and Lupski, {J. R.} and N. Latov and Lewis, {R. A.} and Low, {P. A.} and Fisher, {M. A.} and D. Herrmann and Howard, {J. F.} and G. Lauria and Miller, {R. G.} and M. Polydefkis and Sumner, {A. J.}",
year = "2009",
month = "1",
doi = "10.1002/mus.21227",
language = "English",
volume = "39",
pages = "106--115",
journal = "Muscle and Nerve",
issn = "0148-639X",
publisher = "John Wiley and Sons Inc.",
number = "1",

}

TY - JOUR

T1 - Evaluation of distal symmetric polyneuropathy

T2 - The role of autonomic testing, nerve biopsy, and skin biopsy (an evidence-based review)

AU - England, J. D.

AU - Gronseth, G. S.

AU - Franklin, G.

AU - Carter, G. T.

AU - Kinsella, L. J.

AU - Cohen, J. A.

AU - Asbury, A. K.

AU - Szigeti, K.

AU - Lupski, J. R.

AU - Latov, N.

AU - Lewis, R. A.

AU - Low, P. A.

AU - Fisher, M. A.

AU - Herrmann, D.

AU - Howard, J. F.

AU - Lauria, G.

AU - Miller, R. G.

AU - Polydefkis, M.

AU - Sumner, A. J.

PY - 2009/1

Y1 - 2009/1

N2 - Distal symmetric polyneuropathy (DSP) is the most common variety of neuropathy. Since the evaluation of this disorder is not standardized, the available literature was reviewed to provide evidence-based guidelines regarding the role of autonomic testing, nerve biopsy, and skin biopsy for the assessment of polyneuropathy. A literature review using MEDLINE, EMBASE, Science Citation Index, and Current Contents was performed to identify the best evidence regarding the evaluation of polyneuropathy published between 1980 and March 2007. Articles were classified according to a four-tiered level of evidence scheme and recommendations were based on the level of evidence. (1) Autonomic testing may be considered in the evaluation of patients with polyneuropathy to document autonomic nervous system dysfunction (Level B). Such testing should be considered especially for the evaluation of suspected autonomic neuropathy (Level B) and distal small fiber sensory polyneuropathy (SFSN) (Level C). A battery of validated tests is recommended to achieve the highest diagnostic accuracy (Level B). (2) Nerve biopsy is generally accepted as useful in the evaluation of certain neuropathies as in patients with suspected amyloid neuropathy, mononeuropathy multiplex due to vasculitis, or with atypical forms of chronic inflammatory demyelinating polyneuropathy (CIDP). However, the literature is insufficient to provide a recommendation regarding when a nerve biopsy may be useful in the evaluation of DSP (Level U). (3) Skin biopsy is a validated technique for determining intraepidermal nerve fiber (IENF) density and may be considered for the diagnosis of DSP, particularly SFSN (Level C). There is a need for additional prospective studies to define more exact guidelines for the evaluation of polyneuropathy.

AB - Distal symmetric polyneuropathy (DSP) is the most common variety of neuropathy. Since the evaluation of this disorder is not standardized, the available literature was reviewed to provide evidence-based guidelines regarding the role of autonomic testing, nerve biopsy, and skin biopsy for the assessment of polyneuropathy. A literature review using MEDLINE, EMBASE, Science Citation Index, and Current Contents was performed to identify the best evidence regarding the evaluation of polyneuropathy published between 1980 and March 2007. Articles were classified according to a four-tiered level of evidence scheme and recommendations were based on the level of evidence. (1) Autonomic testing may be considered in the evaluation of patients with polyneuropathy to document autonomic nervous system dysfunction (Level B). Such testing should be considered especially for the evaluation of suspected autonomic neuropathy (Level B) and distal small fiber sensory polyneuropathy (SFSN) (Level C). A battery of validated tests is recommended to achieve the highest diagnostic accuracy (Level B). (2) Nerve biopsy is generally accepted as useful in the evaluation of certain neuropathies as in patients with suspected amyloid neuropathy, mononeuropathy multiplex due to vasculitis, or with atypical forms of chronic inflammatory demyelinating polyneuropathy (CIDP). However, the literature is insufficient to provide a recommendation regarding when a nerve biopsy may be useful in the evaluation of DSP (Level U). (3) Skin biopsy is a validated technique for determining intraepidermal nerve fiber (IENF) density and may be considered for the diagnosis of DSP, particularly SFSN (Level C). There is a need for additional prospective studies to define more exact guidelines for the evaluation of polyneuropathy.

KW - Distal symmetric polyneuropathy

KW - Evaluation

KW - Prospective studies

UR - http://www.scopus.com/inward/record.url?scp=60549087533&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=60549087533&partnerID=8YFLogxK

U2 - 10.1002/mus.21227

DO - 10.1002/mus.21227

M3 - Article

VL - 39

SP - 106

EP - 115

JO - Muscle and Nerve

JF - Muscle and Nerve

SN - 0148-639X

IS - 1

ER -